AbbVie prices $9.93 billion in senior notes to help fund Apogee acquisition
AbbVie agreed on August 4, 2026 to sell $9.93 billion in net proceeds of senior notes across eight series maturing from 2028 to 2066. The company says it will use the proceeds to fund part of the cash payments for its acquisition of Apogee Therapeutics and for general corporate purposes, including debt repayment or repurchase. The offering adds debt to the balance sheet, but it also reduces commitments under a $10.0 billion term loan facility that was arranged for the Apogee deal.
Key points
- Eight series of notes totaling $9.93 billion in estimated net proceeds, including $1.5 billion of 4.875% notes due 2031 and $1.5 billion of 5.300% notes due 2036
- Proceeds are expected to fund part of the cash payments for the Apogee Therapeutics acquisition
- Closing is expected on August 18, 2026, subject to customary closing conditions
- Net proceeds will reduce commitments under the $10.0 billion 364-Day delayed draw term loan facility
The filing
Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.